Bicycle therapeutics announces further expansion of genentech immuno-oncology collaboration

Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced that genentech, a member of the roche group, has exercised its second option to initiate a new program, expanding the exclusive strategic collaboration agreement with bicycle to discover, develop and commercialize novel bicycle®-based immuno-oncolog
BCYC Ratings Summary
BCYC Quant Ranking